Introduction
Botox is the name everyone knows. Dysport and Xeomin are the other two botulinum toxin type A neuromodulators you'll hear about, and all three temporarily soften expression lines.
So why compare them? Formulation, approved treatment areas, unit systems, onset, and injector technique all shape which one fits a given face. A 2016 head-to-head trial even found the three products were not equivalent at the doses studied.
This guide covers what they share and where they differ, without crowning a universal winner. It also explains how Dr. Leonard Grossman, a Brooklyn, NYC plastic surgeon who works with Botox, Dysport, Xeomin, Jeuveau, Daxxify, and Myobloc, decides which product fits a patient. A qualified medical professional still needs to assess your anatomy, goals, and medical history.
Key Takeaways
- All three relax muscles the same way but differ in formulation, labeling, and units.
- Per-unit prices can't be compared across brands, so they don't predict total cost.
- Xeomin lacks accessory proteins, which doesn't guarantee against allergy or resistance.
- The best fit depends on treatment area, prior response, budget, and injector skill.
- When type A products stop working, Dr. Grossman turns to Myobloc, a type B toxin.
Botox vs Dysport vs Xeomin: Quick Comparison
Shared mechanism and purpose
FDA labels describe all three as acetylcholine-release inhibitors. They reduce nerve-to-muscle signaling, which relaxes selected muscles.
That works best on dynamic lines, the ones that appear when you frown or squint. Static lines at rest, caused by skin laxity, sun damage, or volume loss, respond less.
Each product has its own FDA-approved cosmetic indications. Treating other areas is a clinical judgment call and counts as off-label use.
| Product | FDA-approved cosmetic areas |
|---|---|
| Botox Cosmetic | Glabellar lines (2002), lateral canthal lines (2013), forehead lines (2017), platysma bands (2024) |
| Dysport | Glabellar lines (2009), adults under 65 |
| Xeomin | Glabellar lines (2011); forehead and lateral canthal lines added in 2024 |
Formulation and accessory proteins
- Botox: onabotulinumtoxinA, a type A neurotoxin complex with human albumin and sodium chloride. Vials come in 50 and 100 units.
- Dysport: abobotulinumtoxinA complex with human albumin and lactose; label notes possible trace cow's-milk protein. Vials hold 300 or 500 units.
- Xeomin: incobotulinumtoxinA, with the active ingredient separated from accessory proteins. It contains human albumin and sucrose.
A peer-reviewed review discusses a possible link between accessory proteins and immunogenicity. Its clinical relevance in aesthetic use remains uncertain. Xeomin's label makes no claim of lower allergy or resistance risk and still contraindicates known hypersensitivity.
Diffusion and precision
Spread is generally accepted, but its extent and importance are disputed. Dose, volume, dilution, depth, and placement all matter.
A small 2008 skin study found similar anhidrotic areas for Botox and Dysport at matched concentrations. That was not a facial precision test.
No evidence establishes that one brand reliably spreads less. Treat "Dysport spreads more" as a tendency some injectors report, not a rule.
Onset and duration
- Botox: effect begins in 1-2 days and builds over the first week. Glabellar results last about 3-4 months.
- Dysport: onset most often 2-3 days; duration most often four months (about 3-6 months), per a 2021 systematic review.
- Xeomin: median onset is 2-7 days, with effects up to 12-16 weeks.
These ranges overlap heavily. Full effects can take about two weeks. Muscle strength, metabolism, dose, and area all change your own timeline. Dr. Grossman's practice gives a similar timeline for neuromodulators in general: improvement within a few days, the full effect at one to two weeks, and results lasting two to four months, sometimes considerably longer.
Cost and units
Units are product-specific and not interchangeable. Labeled glabellar doses are 20 units for Botox, 50 for Dysport, and 20 for Xeomin. That is not a conversion ratio.
The American Society of Plastic Surgeons tracks a national average for botulinum toxin treatment, but it blends all three brands, every treated area, and every region. Cost varies significantly by location and by how many units your muscles need, so it is not a New York quote.
Compare the total quote for the same area, including recommended units, injector expertise, and follow-up policy. At Dr. Grossman's practice, the price depends on which neuromodulator is used, how many areas are treated, your goals, and how often you return. He gives a personalized quote at consultation rather than a per-unit menu, and financing options are available.
What Are Botox, Dysport, and Xeomin?
Neuromodulators temporarily relax targeted muscles. They are mainly for dynamic expression lines, not every wrinkle. Fillers and other approaches handle volume loss and static lines.
Botox
Botox is onabotulinumtoxinA, with the longest list of cosmetic approvals of the three. Its long track record is appealing, but not proof of superiority. Placement, dose, and how much movement you want to keep matter more than name recognition.
Dysport
Dysport is abobotulinumtoxinA. Some injectors consider it for broader areas. People often say it works faster or costs less per unit. Comparative studies don't clearly back the speed claim, and more units are typically used, so the per-unit price misleads.
Xeomin
Xeomin is incobotulinumtoxinA, often called a "naked" neurotoxin because it lacks accessory proteins. A provider may discuss it if you prefer that formulation or noticed a reduced response elsewhere. It isn't proven to fix resistance.
Use cases, limitations, and safety screening
Neuromodulators may suit forehead lines, glabellar lines, and crow's feet. Significant laxity or volume loss needs a different or added approach.
Prescribing information flags these screening points:
- Prior hypersensitivity to the toxin or its components (Dysport also flags cow's-milk-protein allergy)
- Infection at the injection site
- Neuromuscular disorders
- Medications that affect neuromuscular transmission, such as aminoglycosides
- Pregnancy or breastfeeding, where data are inadequate
All three carry a boxed warning about distant spread of toxin effect. Choose a licensed, trained physician who can assess your anatomy and manage complications, and ask where the treatment takes place. Dr. Grossman injects at his fully accredited (AAAHC) surgery center in Brooklyn. The FDA has also warned about illegal unapproved toxin products.
Botox vs Dysport vs Xeomin: What Is Better?
"Better" depends on your goal, treatment area, previous response, budget, and safety profile. No universal ranking exists.
Goal-based starting points
- Botox: familiar, targeted treatment with the widest set of approved areas.
- Dysport: some injectors consider it for broader areas, though evidence on spread is mixed.
- Xeomin: an accessory-protein-free formulation.
These are conversation starters, not self-selection rules. The same product can behave differently in different people. Dr. Grossman's own neuromodulator page sums it up in one line: the products "differ in formulation, onset of action, and duration of effects," and he recommends the best option for each patient.
Compare cost fairly
When you compare quotes, ask about:
- Total estimated cost for the full treatment
- Recommended units and the treated area
- Follow-up policy
- Whether pricing reflects product-specific dosing
A per-unit price alone, for any of the three, does not tell you the total cost.
Treatment history and response
If a treatment faded early, left too much or too little movement, or spread beyond the target, tell your provider. Apparent resistance has several explanations. Insufficient dose and targeting are more common than neutralizing antibodies, which are rare. Seek evaluation rather than automatically switching brands. For patients who genuinely stop responding to Botox, Dysport, Xeomin, Jeuveau, or Daxxify, Dr. Grossman draws on his long experience with Myobloc, a botulinum toxin type B that his practice reports begins working within a few hours rather than days.
Provider technique
Accurate assessment, conservative dosing, precise placement, and proper handling strongly influence natural-looking results. A provider may use different products over time. Don't switch or combine without discussing timing, dosing, and history.
Brand matters less than placement: Dr. Grossman's view is that results that drift or disappoint usually trace back to how the injection was done. His sessions usually take under 10 minutes with only a small pinch. Treatment uses fine needles, with no incisions or stitches. Dr. Grossman doses conservatively and places each injection precisely for natural-looking results that keep your expressions. Most patients resume their usual routine afterward, following his personalized aftercare instructions.
Consultation checklist
- Which product do you recommend, and why?
- Is the planned area FDA-approved?
- How many product-specific units are proposed?
- What results and downtime are realistic?
- What are the risks, alternatives, and follow-up plans?
Real World Examples/Case Studies
Head-to-head trials show how these decisions play out. In the 2016 trial of 73 treatment-naive women, 20 units of Botox, 60 units of Dysport, and 20 units of Xeomin were compared on glabellar strain.
Strain reduction by brand:
- Day 14: 66.1% Botox, 51.4% Dysport, 42.8% Xeomin
- Day 90: 43.5% Botox, 38.4% Dysport, 25.3% Xeomin
Those figures have limits. The trial enrolled only women, used one glabellar protocol, and measured objective strain rather than patient-perceived results. A separate 224-patient study found Botox and Xeomin responder rates of 96% and 95% at day 28.
Results still depend on dose and treatment area, so no single brand fits everyone. If you're considering facial rejuvenation, schedule a consultation with Dr. Leonard Grossman to discuss whether a neuromodulator or another option suits your goals, medical history, and anatomy. He sees patients at his fully accredited surgery center at 3039 Emmons Ave in Brooklyn, NYC, where the consultation can often be combined with treatment.
Conclusion
Botox, Dysport, and Xeomin share a purpose but differ in formulation, dosing, approved uses, and cost structure. Which option fits best depends on the patient.
Compare total treatment plans, not per-unit prices, and verify product-specific details with your injector. A practice that offers several neuromodulators, as Dr. Grossman's does, can match the product to you instead of fitting you to the one product it stocks. Prioritize qualified medical guidance, realistic expectations, natural-looking results, and proper follow-up when you decide.
Frequently Asked Questions
Which lasts longer, Dysport or Xeomin?
Evidence overlaps. Dysport reviews most often report about four months, and Xeomin's label says up to 12-16 weeks. Dose, muscle activity, and technique matter more.
How long does it take for Xeomin to kick in?
The label gives a median onset of 2-7 days. Full effects may take about two weeks, so follow your provider's instructions.
Does Xeomin wear off faster than Botox?
Labeled estimates (12-16 weeks versus 3-4 months) broadly overlap. Perceived wear-off often reflects dose, anatomy, muscle activity, or area.
Why is Dysport cheaper than Botox?
It often looks cheaper per unit, but each product uses its own units, and Dysport typically requires more of them. Total cost for the same area may be similar or different depending on the plan, your muscle strength, and the dose.
Should I get Botox, Dysport, or Xeomin?
It depends on your goals, anatomy, medical history, prior response, and a qualified injector's recommendation. Dr. Grossman chooses among six neuromodulators after assessing your facial structure, skin, and goals.
Why would someone choose Xeomin over Botox?
Some prefer its accessory-protein-free formulation. That is not a guarantee about allergies, resistance, onset, or longevity.
